Clinical Study

Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes

Figure 1

Mean daily dosages of tapentadol PR administered in 25 diabetic patients with chronic pain consequent on peripheral artery disease (PAD).